P21 Expressing Monocytes for Cancer Cell Therapy
US-2026061029-A1 · Mar 5, 2026 · US
Virus like particles [VLP]
Virus like particles [VLP] · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C12N2740/15023 |
| Official title | Virus like particles [VLP] |
| Display label | Virus like particles [VLP] |
| Total patents | 50 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is growing.
| Year | Patents |
|---|---|
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 8 |
| 2022 | 8 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 11 |
| 2026 | 3 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
US-12559769-B2 · Feb 24, 2026 · US
P21 expressing monocytes for cancer cell therapy
US-12514902-B2 · Jan 6, 2026 · US
Multivalent virus like particle vaccines
US-12502425-B2 · Dec 23, 2025 · US
Compositions comprising cell lines and methods of generating viral particles using the same
US-2025313829-A1 · Oct 9, 2025 · US
VLP-based monovalent ebola vaccines and methods of making and using same
US-12427190-B2 · Sep 30, 2025 · US
Vector system for expressing regulatory RNA
US-12410445-B2 · Sep 9, 2025 · US
LDLR negative packaging cell line for the production of VSV-G pseudotyped retroviral vector particles or virus particles thereof
US-12286639-B2 · Apr 29, 2025 · US
VLP-based bivalent Ebola vaccines and methods of making and using same
US-12280100-B2 · Apr 22, 2025 · US
Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine
US-2025090655-A1 · Mar 20, 2025 · US
Engineered pnma proteins and delivery systems thereof
US-2025064976-A1 · Feb 27, 2025 · US
Cell-type specific membrane fusion proteins
US-2025057984-A1 · Feb 20, 2025 · US
Method of inhibiting enveloped virus binding to target cells by incorporating P-selectin glycoprotein ligand-1 (PSGL-1) into virions
US-12194087-B2 · Jan 14, 2025 · US
Antisense transfer vectors and methods of use thereof
US-2025009802-A1 · Jan 9, 2025 · US
Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
US-2024277829-A1 · Aug 22, 2024 · US
Vlp-based bivalent ebola vaccines and methods of making and using same
US-2024131141-A1 · Apr 25, 2024 · US
Retroviral And Lentiviral Vectors
US-2024093232-A1 · Mar 21, 2024 · US
VLP-based bivalent ebola vaccines and methods of making and using same
US-11890337-B2 · Feb 6, 2024 · US
Retroviral and lentiviral vectors
US-11591613-B2 · Feb 28, 2023 · US
Vector system for expressing regulatory rna
US-2022372513-A1 · Nov 24, 2022 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C12N2740/15023?
- CPC C12N2740/15023 is the Cooperative Patent Classification code for “Virus like particles [VLP].”
- How many patents are filed under CPC C12N2740/15023 (Virus like particles [VLP])?
- Our database includes 50 publications tagged with this CPC code.
- Is patent activity under CPC C12N2740/15023 growing?
- Publication counts under this code: 4 in 2024 vs 11 in 2025 (latest complete years).